首页> 外文期刊>Nature clinical practice. Rheumatology >Biologic agents and liver toxicity: an added concern or therapeutic opportunity?
【24h】

Biologic agents and liver toxicity: an added concern or therapeutic opportunity?

机译:生物制剂和肝毒性:是额外的关注还是治疗机会?

获取原文
获取原文并翻译 | 示例
           

摘要

Biologic agents have transformed the armamentarium of available treatments for chronic inflammatory conditions. Tumor necrosis factor (TNF) inhibitors have proven to be highly effective, but are also associated with a variety of uncommon but serious toxic effects. These toxicities are well established and include risk of infection, malignancy and a number of other disorders, many of which seem to have autoimmune mechanisms. Surprisingly, therefore, the effects of biologic agents (including TNF inhibitors, rituximab and tocilizumab) on the liver have only recently come to light as both a problem because of potential toxicity, and as an opportunity for further indications of clinical efficacy. The issues that surround the potential effects of biologic agents on the liver can be more conveniently viewed as infectious and non-infectious.
机译:生物制剂已经改变了慢性炎性疾病的现有治疗方法。肿瘤坏死因子(TNF)抑制剂已被证明是高度有效的,但也与多种罕见但严重的毒性作用有关。这些毒性是公认的,包括感染,恶性肿瘤和许多其他疾病的风险,其中许多似乎具有自身免疫机制。因此,令人惊讶的是,由于潜在的毒性,生物制剂(包括TNF抑制剂,利妥昔单抗和托珠单抗)对肝脏的作用直到最近才被发现,这既是一个问题,又是进一步证明临床疗效的机会。围绕生物制剂对肝脏潜在影响的问题可以更方便地视为具有传染性和非传染性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号